JP5149172B2 - 乾燥カルニチン粉末又は顆粒を製造するための噴霧乾燥方法 - Google Patents
乾燥カルニチン粉末又は顆粒を製造するための噴霧乾燥方法 Download PDFInfo
- Publication number
- JP5149172B2 JP5149172B2 JP2008519856A JP2008519856A JP5149172B2 JP 5149172 B2 JP5149172 B2 JP 5149172B2 JP 2008519856 A JP2008519856 A JP 2008519856A JP 2008519856 A JP2008519856 A JP 2008519856A JP 5149172 B2 JP5149172 B2 JP 5149172B2
- Authority
- JP
- Japan
- Prior art keywords
- carnitine
- dry
- powder
- drying
- starting material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960004203 carnitine Drugs 0.000 title claims abstract description 104
- 239000000843 powder Substances 0.000 title claims abstract description 97
- 239000008187 granular material Substances 0.000 title claims abstract description 64
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 26
- 238000001694 spray drying Methods 0.000 title claims description 24
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 title abstract 2
- 239000007858 starting material Substances 0.000 claims abstract description 63
- -1 carnitine compound Chemical class 0.000 claims abstract description 28
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 209
- 238000000034 method Methods 0.000 claims description 90
- 239000000047 product Substances 0.000 claims description 55
- 238000001035 drying Methods 0.000 claims description 49
- 239000007788 liquid Substances 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 40
- 230000008569 process Effects 0.000 claims description 35
- 238000000746 purification Methods 0.000 claims description 31
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 29
- 239000012466 permeate Substances 0.000 claims description 23
- 150000001875 compounds Chemical class 0.000 claims description 21
- 244000005700 microbiome Species 0.000 claims description 19
- 239000002243 precursor Substances 0.000 claims description 16
- 238000000108 ultra-filtration Methods 0.000 claims description 16
- 230000002210 biocatalytic effect Effects 0.000 claims description 15
- 238000000855 fermentation Methods 0.000 claims description 14
- 230000004151 fermentation Effects 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 13
- GUYHPGUANSLONG-SNAWJCMRSA-N (E)-4-(trimethylammonio)but-2-enoate Chemical group C[N+](C)(C)C\C=C\C([O-])=O GUYHPGUANSLONG-SNAWJCMRSA-N 0.000 claims description 10
- 239000000377 silicon dioxide Substances 0.000 claims description 10
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 8
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 6
- 235000015099 wheat brans Nutrition 0.000 claims description 6
- 229960003237 betaine Drugs 0.000 claims description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 4
- 150000001845 chromium compounds Chemical group 0.000 claims description 4
- 239000005909 Kieselgur Substances 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000000126 substance Substances 0.000 description 46
- 239000002245 particle Substances 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 20
- 239000000463 material Substances 0.000 description 17
- JHPNVNIEXXLNTR-UHFFFAOYSA-N 4-(trimethylammonio)butanoate Chemical compound C[N+](C)(C)CCCC([O-])=O JHPNVNIEXXLNTR-UHFFFAOYSA-N 0.000 description 14
- 239000007921 spray Substances 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 239000012876 carrier material Substances 0.000 description 11
- 239000012530 fluid Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 235000013305 food Nutrition 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000012467 final product Substances 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000036983 biotransformation Effects 0.000 description 7
- 230000000813 microbial effect Effects 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- AUSHDAODAXKKDJ-FYZOBXCZSA-N (3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate;magnesium Chemical compound [Mg].C[N+](C)(C)C[C@H](O)CC([O-])=O AUSHDAODAXKKDJ-FYZOBXCZSA-N 0.000 description 5
- 102000004157 Hydrolases Human genes 0.000 description 5
- 108090000604 Hydrolases Proteins 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000000889 atomisation Methods 0.000 description 5
- 239000000356 contaminant Substances 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 229910052721 tungsten Inorganic materials 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical group OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 239000011859 microparticle Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- GADIJPCDIWZEMB-BTNVMJJCSA-N (2r,3r)-2,3-dihydroxybutanedioate;hydron;(3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C[N+](C)(C)C[C@H](O)CC([O-])=O.C[N+](C)(C)C[C@H](O)CC([O-])=O GADIJPCDIWZEMB-BTNVMJJCSA-N 0.000 description 3
- 101710088194 Dehydrogenase Proteins 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 102000005488 Thioesterase Human genes 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000003674 animal food additive Substances 0.000 description 3
- 235000010216 calcium carbonate Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000011143 downstream manufacturing Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 235000012041 food component Nutrition 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000005417 food ingredient Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 108020002982 thioesterase Proteins 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N (+)-Erythro-hydroxycitric acid Natural products OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 description 2
- ZMJBYMUCKBYSCP-AWFVSMACSA-N (1s,2r)-1,2-dihydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)[C@@H](O)[C@@](O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-AWFVSMACSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 241000589158 Agrobacterium Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000589180 Rhizobium Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000002535 acidifier Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000010352 biotechnological method Methods 0.000 description 2
- 238000013452 biotechnological production Methods 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 229940046374 chromium picolinate Drugs 0.000 description 2
- GJYSUGXFENSLOO-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 GJYSUGXFENSLOO-UHFFFAOYSA-N 0.000 description 2
- 239000011362 coarse particle Substances 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000004042 decolorization Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 235000019136 lipoic acid Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- YJQZYXCXBBCEAQ-UHFFFAOYSA-N ractopamine Chemical group C=1C=C(O)C=CC=1C(O)CNC(C)CCC1=CC=C(O)C=C1 YJQZYXCXBBCEAQ-UHFFFAOYSA-N 0.000 description 2
- 229940074095 ractopamine Drugs 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960002663 thioctic acid Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- BQMPVGMHZKZPBH-BYZBDTJCSA-N (3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O.C[N+](C)(C)C[C@H](O)CC([O-])=O BQMPVGMHZKZPBH-BYZBDTJCSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- RZALONVQKUWRRY-FYZOBXCZSA-N 2,3-dihydroxybutanedioic acid;(3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical compound OC(=O)C(O)C(O)C(O)=O.C[N+](C)(C)C[C@H](O)CC([O-])=O RZALONVQKUWRRY-FYZOBXCZSA-N 0.000 description 1
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
- 108010046716 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) Proteins 0.000 description 1
- NXDDNODAJKZARA-UHFFFAOYSA-N 4-(dimethylazaniumyl)-3-hydroxybutanoate Chemical compound CN(C)CC(O)CC(O)=O NXDDNODAJKZARA-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229910021532 Calcite Inorganic materials 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000819038 Chichester Species 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108010020056 Hydrogenase Proteins 0.000 description 1
- 108010093096 Immobilized Enzymes Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical group CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 1
- QWYFHHGCZUCMBN-SECBINFHSA-N O-butanoyl-L-carnitine Chemical group CCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C QWYFHHGCZUCMBN-SECBINFHSA-N 0.000 description 1
- UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical group CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 description 1
- VSNFQQXVMPSASB-SNVBAGLBSA-N O-valeroyl-L-carnitine Chemical group CCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C VSNFQQXVMPSASB-SNVBAGLBSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 102000012751 Pyruvate Dehydrogenase Complex Human genes 0.000 description 1
- 108010090051 Pyruvate Dehydrogenase Complex Proteins 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000010793 Steam injection (oil industry) Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 239000012615 aggregate Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 239000011942 biocatalyst Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 238000011138 biotechnological process Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 108010029922 carnitine dehydrogenase Proteins 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 150000001844 chromium Chemical class 0.000 description 1
- HPCCGRCEBFBZQP-UHFFFAOYSA-N chromium;pyridine-3-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CN=C1 HPCCGRCEBFBZQP-UHFFFAOYSA-N 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000007357 dehydrogenase reaction Methods 0.000 description 1
- 238000000280 densification Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- IGQBPDJNUXPEMT-SNVBAGLBSA-N isovaleryl-L-carnitine Chemical compound CC(C)CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IGQBPDJNUXPEMT-SNVBAGLBSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000004466 pelleted feed Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 235000019353 potassium silicate Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000010069 protein adhesion Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K40/00—Shaping or working-up of animal feeding-stuffs
- A23K40/10—Shaping or working-up of animal feeding-stuffs by agglomeration; by granulation, e.g. making powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/007—Carnitine; Butyrobetaine; Crotonobetaine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Animal Husbandry (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Vaporization, Distillation, Condensation, Sublimation, And Cold Traps (AREA)
Description
a)出発材料を担体と混合し、
b)a)で得られた混合物を乾燥方法に付し、及び
c)安定な乾燥カルニチン粉末又は顆粒を回収する
工程を包含する乾燥カルニチン粉末又は顆粒を製造する第1方法を提供して、この技術的課題を解決する。
a)出発材料を乾燥方法に付して乾燥生成物を得て
b)a)で得られた乾燥生成物を担体と混合し、及び
c)安定な乾燥カルニチン粉末又は顆粒を回収する
工程を包含するカルニチン含有液体出発材料から乾燥カルニチン粉末又は顆粒を調製する第2方法を提供することによってもこの技術的課題を解決する。
a) 出発材料を予備精製、特に1の精製工程に付し、
b) この予備精製した出発材料と担体を混合し、
c) b)で得られた混合物を乾燥法に付し、
d) 低水含量の安定な乾燥カルニチン粉末又は顆粒を回収する工程
を包含する、カルニチン化合物を含む未精製液状出発材料から乾燥カルニチン化合物を含有する乾燥カルニチン粉末又は顆粒を調製する方法に関する。
a) 出発材料を予備精製、特に1の精製工程に付し、
b) プレ精製出発材料を乾燥法に付して乾燥製品を得て、
c) b)で得られた乾燥生成物を担体と混合し、
d) 低水含量の安定な乾燥カルニチン粉末又は顆粒を回収する工程
を包含する、カルニチン化合物を含有する未精製液状出発材料から乾燥カルニチン粉末又は顆粒を調製する方法に関する。
a) 液状媒体内でL-カルニチンを製造するバイオ触媒法を行い、
b) 該媒体をプレ精製工程に付してL-カルニチンを含むプレ精製液体を得て、
c) 乾燥製品を得るためにプレ精製した液体を乾燥法に付しかつ乾燥した乾燥生成物を担体と混合し、又はプレ精製した液体を担体と混合しかつ得られた混合物を乾燥法に付し、及び
d) L-カルニチンの乾燥粉末を得る工程を包含する方法である。
L-カルニチンを含むプレ精製原料
L-カルニチン限外濾過透過物1(L-カルニチン=8.02%W/W、乾燥物9.87%W/W、塩+不純物1.85%、pH=6.5)
L-カルニチン限外濾過透過物2(L-カルニチン=7.90%W/W、乾燥物9.35%W/W、塩+不純物1.45%W/W、pH=7.0)
担体材料:
小麦ふすまバッチNo.S−224/04、製粉したCaCO3(S−219/04)
Sipernat50、Sipernat2200、Sipernat22、SilicasilMG、TIX−O−SIL68、DiamolDI100g
装置:
キッチンブレンダーETA0010
実験室スプレイドライヤ 渦巻アトマイザー付き(Anhydro)
ペーストの乾燥用実験室渦巻ドライヤ Funnel試験用セット
方法:
a)混合物の調製
計算量のL-カルニチン限外濾過透過物又は粉末を対応量の担体(及びピコリン酸クロム)を実験室ビーカー又は台所ブレンダーで混合した。
L-カルニチン限外濾過透過物又は懸濁液又はクリームを4℃で貯蔵し、及び実験室噴霧乾燥機で入口/出口温度=250/115−120℃、又は実験室渦巻乾燥機で入口/出口温度=250/115−115℃で乾燥した。
L-カルニチン、4-ブチロベタイン、クロトノベタイン及びノルカルニチン濃度をHPLCで定めた。乾燥物含量を105℃の炉内で定重量になるまで乾燥して定めた。水の含量は古典的なCarlFisher滴定で定めた。最終製品の流動性は流動性測定のための漏斗試験で測定した(Degussaの技術ブレテン顔料No.3参照)。
この実験では、L-カルニチン透過物を噴霧乾燥機で噴霧乾燥し、次いで適当な担体と混合した。透過物をNiroアトマイザー(能力10LH2O/時)で入口温度230℃(出口温度=115℃)で乾燥した。それによって乾燥したが高い吸湿性の粉末(L-カルニチン含量約86.2%)が塊を含んで得られた。粉末は迅速に篩い分けして塊を除き、次いで台所ブレンダーでピコリン酸クロムと場合によって混合する前に各種の量の各種の担体物質と混合した。表1はこうして得られたL-カルニチン粉末の組成を示す。
この実験では、L-カルニチン透過物を担体と混合し、次いで適当な乾燥装置で乾燥した。混合物が液体である場合には噴霧乾燥機を用いた。混合物がペーストの形態を有する場合には渦巻乾燥機を用いた。表2はこうして得られた乾燥L-カルニチン粉末の組成を示す。
この製造実験では、L-カルニチン透過物は担体と混合しかつ次いで適当な乾燥装置で乾燥して流体混合物を得た。乾燥のために流動床を用いた。表4はこうして得られた乾燥L-カルニチンマイクロ粒状物の組成を示す。
Claims (16)
- a) 発酵ブロスの限外濾過で得られた透過物である出発材料を乾燥工程に付して乾燥生成物を得て、
b) a)で得られた乾燥生成物を担体と混合し及び
c) 安定な乾燥カルニチン粉末又は顆粒を回収する工程を包含するカルニチンを含む液状出発物質から乾燥カルニチン粉末又は顆粒を調製する方法。 - 乾燥製品を篩い分けて固まりを除きかつ次いで担体と混合する請求項1に記載の方法。
- カルニチンがL-カルニチン、アルカノイル−L-カルニチン、その誘導体、その塩又はその混合物である請求項1または2に記載の方法。
- 出発材料が溶液、懸濁液又はペーストの形態を有する請求項1〜3のいずれか一項に記載の方法。
- 乾燥工程が噴霧乾燥である請求項1〜4のいずれか一項に記載の方法。
- 乾燥が渦巻乾燥機で行われる請求項1〜5のいずれか一項に記載の方法。
- 担体が小麦ふすま、沈殿シリカ、シリカ粒子、粉状又は顆粒状珪藻土及び炭酸カルシウムからなる群から選ばれる請求項1〜6のいずれか一項に記載の方法。
- 1以上の追加化合物が出発材料又は乾燥前の担体又は乾燥後に得られた乾燥カルニチン粉末に加えられる請求項1〜7のいずれか一項に記載の方法。
- 追加成分がクロム化合物である請求項8に記載の方法。
- 追加成分がアミノ酸である請求項8に記載の方法。
- 乾燥カルニチン粉末が12%未満、好ましくは4%未満の含水量を有する請求項1〜10のいずれか一項に記載の方法。
- 乾燥カルニチン粉末が飼料製品の製造に適する請求項1〜11のいずれか一項に記載の方法。
- a)液状媒体中でL-カルニチン製造のバイオ触媒法を実施し、
b) 媒体をプレ精製工程に付してL-カルニチン含有液体を得、
c) プレ精製液体を請求項1〜12のいずれか一項の方法に付し、かつ
d) 安定な乾燥L-カルニチン粉末又は顆粒を得る工程を包含する飼料製品の製造に特に適した乾燥した実質的に純粋なL-カルニチン粉末又は顆粒の製造方法。 - バイオ触媒法が先駆体を含有する媒体中でL-カルニチンの製造を許容する条件下で適当な先駆体化合物からL-カルニチンを製造することができる少なくとも1の微生物の培養及び媒体中への排出を包含する請求項13に記載の方法。
- プレ精製工程がL-カルニチン含有透過物を得るためのL-カルニチン含有液体媒体の限外濾過を包含する請求項13または14に記載の方法。
- L-カルニチンの先駆体がクロトンベタイン、y−ブチロベタイン、ベタインエステル、又はそれらの混合物である請求項13〜15のいずれか一項記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05014529.1 | 2005-07-05 | ||
EP05014529 | 2005-07-05 | ||
PCT/EP2006/006551 WO2007003425A2 (en) | 2005-07-05 | 2006-07-05 | Spray-drying process for producing a dry carnitine powder or granulate |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009500026A JP2009500026A (ja) | 2009-01-08 |
JP5149172B2 true JP5149172B2 (ja) | 2013-02-20 |
Family
ID=37562145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008519856A Active JP5149172B2 (ja) | 2005-07-05 | 2006-07-05 | 乾燥カルニチン粉末又は顆粒を製造するための噴霧乾燥方法 |
Country Status (11)
Country | Link |
---|---|
US (1) | US9084431B2 (ja) |
EP (1) | EP1901715B1 (ja) |
JP (1) | JP5149172B2 (ja) |
KR (1) | KR101327700B1 (ja) |
CN (2) | CN101912045B (ja) |
AT (1) | ATE555774T1 (ja) |
AU (1) | AU2006265280B2 (ja) |
BR (1) | BRPI0612611A2 (ja) |
CA (1) | CA2611901C (ja) |
ES (1) | ES2385046T3 (ja) |
WO (1) | WO2007003425A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170014179A (ko) * | 2015-07-29 | 2017-02-08 | 제너럴바이오(주) | L-카르니틴 구연산 마그네슘을 포함하는 배변촉진 겸용 다이어트용 식품 조성물 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5463526B2 (ja) * | 2008-03-21 | 2014-04-09 | 国立大学法人東京海洋大学 | 健康機能成分を吸着・濃縮した乾燥脱脂穀類糠、該糠から調製した健康機能成分の濃縮物、及びそれらの製造方法 |
EP2335495A1 (en) * | 2009-12-11 | 2011-06-22 | Lonza Ltd. | Carnitine granulate and methods for its production |
PL2729015T3 (pl) * | 2011-07-08 | 2019-07-31 | Purac Biochem Bv | Aktywna formulacja do stosowania w produktach paszowych |
KR20150082317A (ko) | 2012-11-16 | 2015-07-15 | 론자 아게 (론자 엘티디.) | 베타인류를 포함하는 조성물의 탈색 방법 |
CN106957238A (zh) * | 2017-04-19 | 2017-07-18 | 黄冈华阳药业有限公司 | 一种肉碱的制备工艺 |
JP7240098B2 (ja) * | 2018-01-17 | 2023-03-15 | 昭和産業株式会社 | 飼料原料及び飼料 |
US11785966B2 (en) | 2019-03-06 | 2023-10-17 | Anipha Technologies Pty Ltd | Use of gamma-quaternary ammonium butyrate compound in preparation of an animal feed additive |
CN111838421B (zh) * | 2020-07-27 | 2023-04-21 | 中国科学院天津工业生物技术研究所 | 一种从发酵液中制备5-氨基乙酰丙酸的方法及其应用 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3463261D1 (en) * | 1983-12-28 | 1987-05-27 | Sigma Tau Ind Farmaceuti | Salts of l-carnitine and alkanoyl l-carnitines and process for preparing same |
FI86889C (fi) * | 1984-03-29 | 1992-10-26 | Lonza Ag | Foerfarande foer framstaellning av av l-karnitin pao mikrobiologiskt saett |
US4751182A (en) * | 1984-04-20 | 1988-06-14 | Wisconsin Alumni Research Foundation | Process for preparing L-carnitine from DL-carnitine |
CA2018137C (en) | 1989-06-14 | 2000-01-11 | Thomas Scholl | L-carnitine magnesium citrate |
WO1991001728A1 (en) | 1989-07-31 | 1991-02-21 | University Of Georgia Research Foundation, Inc. | Carnitine supplemented finishing pig diet |
JPH03120211A (ja) * | 1989-10-04 | 1991-05-22 | Earth Chem Corp Ltd | 粒状カルニチン製剤 |
US5073376A (en) | 1989-12-22 | 1991-12-17 | Lonza Ltd. | Preparations containing l-carnitine |
GB9107628D0 (en) | 1991-04-10 | 1991-05-29 | Moonbrook Limited | Preparation of diagnostic agents |
GB9221329D0 (en) | 1992-10-10 | 1992-11-25 | Delta Biotechnology Ltd | Preparation of further diagnostic agents |
ATE257515T1 (de) | 1993-10-08 | 2004-01-15 | Lonza Ag | Gene für den butyrobetain/crotonobetain-l- carnitin-stoffwechsel und ihre verwendung zur mikrobiologischen herstellung von l-carnitin |
JPH0812569A (ja) * | 1994-06-24 | 1996-01-16 | Takeda Chem Ind Ltd | 塩化カルニチン吸着固形物 |
IT1289974B1 (it) * | 1997-02-25 | 1998-10-19 | Aldo Fassi | Procedimento per la produzione di sali stabili e non igroscopici di l(-)carnitina e di alcanoli l(-)-carnitine |
EP0914315B1 (en) * | 1996-05-31 | 2001-04-11 | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. | Stable, non-hygroscopic salts of l(-)carnitine and alkanoyl l(-)carnitines, a process for their preparation and solid, orally administrable compositions containing such salts |
JP4452341B2 (ja) * | 1999-01-13 | 2010-04-21 | 雪印乳業株式会社 | L−カルニチン剤 |
IT1305308B1 (it) * | 1999-03-26 | 2001-05-04 | Biosint S P A | Granulato ad alto contenuto di l-carnitina o alcanoil-l-carnitina,particolarmente adatto alla produzione di compresse per compressione |
DE60041269D1 (de) * | 1999-09-03 | 2009-02-12 | Sigma Tau Healthscience Spa | Ultrafeines l-carnitin, verfahren zur dessen herstellung, dieses enthaltende zusammensetzungen, sowie verfahren zu dessen verwendung |
WO2002017735A2 (de) | 2000-08-29 | 2002-03-07 | Lonza Ag | Verfahren zur herstellung einer granulierbaren mischung und carnitin-magnesium-hydroxycitrat |
CN1203776C (zh) * | 2000-12-07 | 2005-06-01 | 东北制药总厂 | 左旋肉碱饲料添加剂及其制备方法 |
ATE356214T1 (de) | 2001-01-31 | 2007-03-15 | Lonza Ag | Mikrobiologisches verfahren zur herstellung von l-carnitin |
US7169770B2 (en) * | 2001-04-24 | 2007-01-30 | Lonza Ltd. | Method of enhancing reproductive performance in sows |
WO2003009854A1 (en) * | 2001-07-20 | 2003-02-06 | Lonza Ag | Lipid lowering composition comprising carnitine and phytosterol |
US20030235646A1 (en) | 2002-03-15 | 2003-12-25 | Lonza Inc. | Method for improving quality of meat by supplementing pig diets and concentrates used therefor |
-
2006
- 2006-07-05 CN CN2010102628572A patent/CN101912045B/zh active Active
- 2006-07-05 CN CNA2006800242894A patent/CN101212956A/zh active Pending
- 2006-07-05 CA CA2611901A patent/CA2611901C/en not_active Expired - Fee Related
- 2006-07-05 JP JP2008519856A patent/JP5149172B2/ja active Active
- 2006-07-05 EP EP06776126A patent/EP1901715B1/en active Active
- 2006-07-05 AT AT06776126T patent/ATE555774T1/de active
- 2006-07-05 ES ES06776126T patent/ES2385046T3/es active Active
- 2006-07-05 KR KR1020087002760A patent/KR101327700B1/ko active IP Right Grant
- 2006-07-05 BR BRPI0612611-1A patent/BRPI0612611A2/pt not_active Application Discontinuation
- 2006-07-05 WO PCT/EP2006/006551 patent/WO2007003425A2/en active Application Filing
- 2006-07-05 AU AU2006265280A patent/AU2006265280B2/en not_active Ceased
- 2006-07-05 US US11/988,095 patent/US9084431B2/en active Active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170014179A (ko) * | 2015-07-29 | 2017-02-08 | 제너럴바이오(주) | L-카르니틴 구연산 마그네슘을 포함하는 배변촉진 겸용 다이어트용 식품 조성물 |
KR101721145B1 (ko) * | 2015-07-29 | 2017-03-29 | 제너럴바이오(주) | L-카르니틴 구연산 마그네슘을 포함하는 배변촉진 겸용 다이어트용 식품 조성물 |
Also Published As
Publication number | Publication date |
---|---|
WO2007003425A3 (en) | 2007-03-08 |
US9084431B2 (en) | 2015-07-21 |
CA2611901A1 (en) | 2007-01-11 |
US20090082449A1 (en) | 2009-03-26 |
EP1901715B1 (en) | 2012-05-02 |
CN101912045A (zh) | 2010-12-15 |
KR101327700B1 (ko) | 2013-11-11 |
JP2009500026A (ja) | 2009-01-08 |
CN101212956A (zh) | 2008-07-02 |
EP1901715A2 (en) | 2008-03-26 |
KR20080030650A (ko) | 2008-04-04 |
BRPI0612611A2 (pt) | 2010-12-07 |
CA2611901C (en) | 2012-12-11 |
AU2006265280B2 (en) | 2011-07-14 |
CN101912045B (zh) | 2013-07-31 |
WO2007003425A2 (en) | 2007-01-11 |
ES2385046T3 (es) | 2012-07-17 |
AU2006265280A1 (en) | 2007-01-11 |
ATE555774T1 (de) | 2012-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5149172B2 (ja) | 乾燥カルニチン粉末又は顆粒を製造するための噴霧乾燥方法 | |
US6017555A (en) | Process for making L-lysine feed supplement | |
JP5199094B2 (ja) | 固体形態の不揮発性微生物代謝産物の発酵生産 | |
JP7156594B2 (ja) | 1ステップ発酵による(r)-3-ヒドロキシ酪酸またはその塩の調製 | |
JP4659825B2 (ja) | ファインケミカルの発酵生産 | |
HUE027979T2 (en) | A method of isolating methionine from fermentation broth | |
US6756510B1 (en) | Making a variety of L-lysine feed supplements | |
CN105658080B (zh) | 包含l-氨基酸的饲料添加剂 | |
AU771057B2 (en) | Aqueous lysine-containing animal feed supplements and process for the production thereof | |
TWI642359B (zh) | 生質n-乙醯基-l-甲硫胺酸及其用途 | |
RU2168302C2 (ru) | Способ производства гранул, содержащих салиномицин, и гранулы, полученные этим способом | |
EP1752543A1 (en) | Process for making a variety of l-lysine feed supplements | |
EP1118673B1 (en) | Process for making a variety of L-lysine feed supplements | |
MXPA00007330A (en) | Process for making a variety of l-lysine feed supplements |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090420 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110906 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111202 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121030 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121129 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5149172 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151207 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |